pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastiset aineet - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
dalacin 15 mg/ml rakeet oraaliliuosta varten
pfizer oy - clindamycin palmitate hydrochloride - rakeet oraaliliuosta varten - 15 mg/ml - klindamysiini
dalacin 150 mg/ml injektioneste, liuos
pfizer oy pfizer oy - clindamycini phosphas - injektioneste, liuos - 150 mg/ml - klindamysiini
dalacin 300 mg kapseli
pfizer oy - clindamycin hydrochloride - kapseli - 300 mg - klindamysiini
duphalac 667 mg/ml oraaliliuos
viatris oy - lactulose solution - oraaliliuos - 667 mg/ml - laktuloosi
dalacin 10 mg/ml liuos iholle
pfizer oy pfizer oy - clindamycini phosphas - liuos iholle - 10 mg/ml - klindamysiini
dalacin 10 mg/ml emulsio iholle
pfizer oy - clindamycin phosphate - emulsio iholle - 10 mg/ml - klindamysiini
dalacin 2 % emätinemulsiovoide
pfizer oy - clindamycin phosphate - emätinemulsiovoide - 2 % - klindamysiini
dalacin 150 mg kapseli
pfizer oy - clindamycin hydrochloride - kapseli - 150 mg - klindamysiini
duphalac 950 mg/g jauhe
mylan healthcare b.v. - lactulosum cristallinum - jauhe - 950 mg/g - laktuloosi